Dr. Reddy’s Laboratories Limited (RDY)


Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Dr. Reddy’s Laboratories Limited ("”Dr. Reddy’s" or "the Company") (NYSE: RDY). The investigation concerns whether Dr. Reddy’s and certain of its officers and/or directors have violated federal securities laws.


On January 29, 2021, Dr. Reddy’s issued a press release announcing the Company’s financial results for the quarter and nine months ended December 31, 2020.  Among other results, Dr. Reddy’s posted a lower-than-expected profit for the quarter, citing the impact of “trigger based impairment charges taken on a few acquired products including gNuvaring.”  On this news, Dr. Reddy’s American Depositary Receipt (“ADR”) price fell $4.78 per ADR, or 7.24%, to close at $61.28 per ADR on January 29, 2021.


If you are aware of any facts relating to this investigation, or purchased Dr. Reddy’s shares, you can assist this investigation by visiting contacting the firm. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

© 2020 Bronstein, Gewirtz & Grossman, LLC

  • Twitter Social Icon
  • LinkedIn

BG&G is not affiliated to any of these companies. All respective trademarks are owned by the respective companies.